

Regulatory Affairs

Sponsor	Annette Chiu (GSK)	Objective	<p>To expedite launch of innovative drug for patients To ensure the regulatory requirements cope with medical advances</p>			
			<p>I. System enhancement for existing drug registration process</p>	<p>II. Shape regulatory requirements to cope with medical advances</p>	<p>III. Promote good regulatory practice</p>	<p>IV. Improve engagement with Macao DAF</p>
Lead	Karen Yuen (AbbVie)	Endpoint	<ul style="list-style-type: none"> NCE/New Drug approval in HK further expedited with a predictable timeline 	<ul style="list-style-type: none"> To ensure the regulatory requirements cope with medical advances 	<ul style="list-style-type: none"> Regulatory practices and system improved 	<ul style="list-style-type: none"> Members better understand regulatory framework in Macao
Members	Linda Chan (BMS)					
	Susanna Yim (Janssen)					
	Kim Lee (Novartis)					
	Elaine Tang (Sanofi)					
	Maria Kong (Servier)					
Future State		<ul style="list-style-type: none"> Pharma industry seen as an important partner in healthcare delivery in both HK and Macau Regulatory requirements shaped to cope with medical advances Efficient regulatory system being able to protect public health, while also conducive to pharma industry 				